Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.
The American Journal Of Pathology
Caturegli, Patrizio P; Di Dalmazi, Giulia G; Lombardi, Martina M; Grosso, Federica F; Larman, H Benjamin HB; Larman, Tatianna T; Taverna, Giacomo G; Cosottini, Mirco M; Lupi, Isabella I
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Plos One
Lovly, Christine M CM; Dahlman, Kimberly Brown KB; Fohn, Laurel E LE; Su, Zengliu Z; Dias-Santagata, Dora D; Hicks, Donna J DJ; Hucks, Donald D; Berry, Elizabeth E; Terry, Charles C; Duke, MarKeesa M; Su, Yingjun Y; Sobolik-Delmaire, Tammy T; Richmond, Ann A; Kelley, Mark C MC; Vnencak-Jones, Cindy L CL; Iafrate, A John AJ; Sosman, Jeffrey J; Pao, William W